8-K: VSee Health Secures $201K Convertible Note Financing

VSee Health, Inc. has secured $201,000 in financing through a convertible promissory note and the issuance of 50,000 shares of common stock to an institutional investor.

Summary

• VSee Health, Inc. entered into a Convertible Note Purchase Agreement (CNPA) with an accredited institutional investor, M2B Funding Corp., on October 29, 2025.
• The investor purchased a convertible promissory note with an initial principal amount of $217,391.30 and 50,000 shares of common stock for an aggregate purchase price of $201,000.
• The note accrues interest at 18% per annum, with the first eight months of interest guaranteed and accruing immediately.
• The note matures on October 29, 2026, and interest payments can be made in cash or common stock at the investor's discretion, commencing December 1, 2025.
• The company may prepay 100% of the outstanding balance of the note at any time if not in default, subject to a 10% prepayment fee.
• The investor may convert any portion of the outstanding balance of the note into common stock at a price of $0.48 per share after January 29, 2026, subject to adjustments and a 9.99% beneficial ownership limitation.
• The company's obligations under the note are secured by a security interest on all its assets, junior only to existing finance obligations with Ascent Partners Fund LLC and Dominion Capital LLC.
• The investor has the right, but not the obligation, to purchase another convertible promissory note from the company on the same terms and conditions for up to 12 months after execution of the CNPA or until the company's obligations under the note are no longer outstanding.
• The proceeds from the financing are designated for general working capital, excluding payment of obligations other than trade payables incurred in the ordinary course of business.

Sentiment

Score: 3

Explanation: The financing provides much-needed capital but comes at a very high cost (18% interest, 8% discount) and significant potential for dilution. The all-asset security interest and stringent default terms indicate a high-risk profile for the company, outweighing the benefit of securing funds.

Positives

• Secured $201,000 in financing, providing capital for general working capital.
• The company retains the option to prepay the note, offering flexibility if financial conditions improve.
• The investor's right to purchase an additional note provides a potential future funding source.

Negatives

• High annual interest rate of 18% on the convertible note, with the first eight months guaranteed, indicating a high cost of capital.
• An 8% original issuance discount ($17,391.30 on a $217,391.30 principal for a $200,000 loan) further increases the effective cost of borrowing.
• The note is secured by a security interest on all company assets, which could limit future financing options and increase risk for existing unsecured creditors.
• Potential for significant dilution if the note is converted into common stock, especially given the conversion price of $0.48 per share, which can be further reduced under certain conditions.
• Covenants restrict the company from entering into variable rate transactions and require prepayment from Qualified Financing proceeds, limiting financial flexibility.
• Default interest rate increases to 24% per annum, significantly penalizing the company for any breaches.

Risks

• Dilution Risk: Conversion of the note into common stock at $0.48 per share, or potentially lower due to adjustments, could significantly dilute existing shareholders.
• High Cost of Capital: The 18% annual interest rate and 8% original issuance discount represent a substantial financial burden.
• Asset Encumbrance: All company assets are pledged as security, which could hinder the company's ability to secure additional financing or impact its operations if default occurs.
• Default Risk: The note contains numerous events of default, including failure to pay, breach of covenants, failure to timely deliver common stock upon conversion, and delisting, which could lead to acceleration of the debt and a 20% penalty (Mandatory Default Amount).
• Liquidity Risk: The company's ability to meet interest payments (cash or stock) and the principal repayment on the maturity date, or prepayment obligations, depends on its future financial performance.
• Market Price Volatility: The conversion price is subject to adjustments based on the VWAP, and a low volume condition reset could further reduce the conversion price, exacerbating dilution.
• Regulatory Compliance Risk: Failure to comply with SEC reporting requirements or maintain listing on Nasdaq could trigger an event of default.

Future Outlook

The filing indicates the company intends to use the proceeds from this financing for general working capital. The investor has an option to purchase another convertible note on similar terms for up to 12 months, suggesting a potential future funding source for the company.

Industry Context

This financing event is a common method for smaller public companies, particularly those with limited access to traditional bank financing, to raise capital. The high interest rate and asset-backed security suggest VSee Health may be in a growth phase requiring significant capital or facing challenges in securing less dilutive/expensive funding. The dilutive nature of the convertible note and the low conversion price indicate a potentially distressed or high-growth company seeking immediate capital.

Comparison to Industry Standards

• The 18% annual interest rate and 8% original issuance discount are significantly higher than typical corporate debt for established, profitable companies, suggesting a higher risk profile for VSee Health.
• The conversion price of $0.48 per share, coupled with potential further reductions, indicates a substantial discount to the market price at the time of conversion, which is common in high-risk convertible debt but highly dilutive for existing shareholders.
• The full asset security interest is a strong protection for the investor, M2B Funding Corp., but places VSee Health in a more constrained position compared to companies with unencumbered assets.
• The 9.99% beneficial ownership blocker is a standard provision in such agreements to avoid triggering certain SEC reporting requirements for the investor.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the conversion of the note at a low price, and the high cost of debt could impact future profitability.
• Creditors: The all-asset security interest granted to the new investor (M2B Funding Corp.) subordinates other unsecured creditors, increasing their risk.
• Employees/Customers/Suppliers: The capital infusion for general working capital could stabilize operations, potentially benefiting employees, customers, and suppliers by ensuring continued business activity.

Next Steps

• VSee Health, Inc. will use the $200,000 net proceeds for general working capital.
• Interest payments on the note will commence on December 1, 2025.
• The investor may convert portions of the note into common stock after January 29, 2026.
• The company must comply with various covenants, including maintaining asset security and restrictions on future transactions.
• The investor has an option to purchase another convertible note on similar terms for up to 12 months.

Key Dates

Recommendation

The terms of this financing are highly unfavorable for VSee Health, Inc. The 18% interest rate, 8% original issuance discount, and the all-asset security interest indicate a company in a precarious financial position or one with very limited access to capital. The low conversion price of $0.48 per share, with potential for further reduction, suggests significant future dilution for existing shareholders. The numerous and broad events of default, coupled with a 24% default interest rate and a 120% mandatory default amount, expose the company to substantial downside risk. While the financing provides immediate working capital, the long-term implications of such expensive and dilutive debt are likely to be detrimental to shareholder value. Investors should consider selling due to the high cost of capital, significant dilution risk, and the company's constrained financial flexibility.

Keywords

Convertible Note, Debt Financing, Equity Issuance, SEC Filing, VSee Health, M2B Funding Corp, Dilution, Secured Debt, High Interest Rate, Capital Raise, Form 8-K, Corporate Finance